Abstract:Abstract Background Identifying molecular determinants underpinning response and resistance to anti-cancer therapies is essential to selecting optimal treatment for patients (pts). The PI3K pathway is frequently deregulated in cancer. In preclinical models deregulated PI3K has been shown to enhance the survival of breast cancer cells and confer resistance to chemotherapy and HER2−directed agents. This exploratory study evaluated the impact PIK3CA mutations and PTEN loss had on the efficacy of paclitaxel alone (P) and in combination with lapatinib (L+P) in HER2−positive metastatic breast cancer (MBC) pts enrolled in study EGF104535, results of which demonstrated that pts treated with the combination of L+P derived an absolute improvement in median overall survival (OS) of 7.3.months (median OS=27.8 months in L+P compared with 20.5 months in P). Method Baseline tissue from primary breast tumor or metastatic site was obtained in the form of formalin-fixed, paraffin-embedded material. Of the total study population (n=444), 389 pts had tissue available for biomarker analyses, 277 of whom provided written informed consent for optional tumor genetics (i.e., PIK3CA analysis). PTEN was evaluated on whole sections by immunohistochemistry (rabbit monoclonal antibody); pathology review and image analysis were performed, producing an ordinal score and optical density (OD). Qiagen/DxS assay was used in assessing PIK3CA mutation status. Logistic regression and Cox-proportional hazard models were used in analyses of biomarkers with efficacy endpoints. Results Evaluable results for PTEN and PIK3CA were available for 91% (354/389) and 62% (171/274) of pts, respectively. In the overall population, 24% (65/274) had tumors harboring PIK3CA mutations (E542K, E545K/D, H1047R); 13% (49/389) had absence of PTEN expression. Survival outcome appeared to be independent of PTEN expression (P >0.2). PIK3CA mutations were significantly associated with worse OS (HR=1.88; 95% CI=1.26, 2.80; P=0.002). PFS was significantly improved in pts treated with L+P compared with P in both PTEN strata (loss/expression; P<0.001). In pts stratified by PIK3CA status, treatment with L+P reduced the risk of progression compared with P in the wildtype strata (N=106; HR=0.43; 95% CI=0.28, 0.65; P<0.0001); in the mutation strata, PFS was not significantly reduced with the addition of L (N=65; HR=0.70; 95% CI= 0.42, 1.17; P=0.179). Conclusions In this exploratory study, PTEN was not prognostic whereas PIK3CA mutations appear to be an adverse prognostic feature in HER2+ MBC. PTEN expression may not be predictive as both strata derived significant benefit with L+P treatment. PFS benefit from L+P was significant in pts with PIK3CA wildtype tumors whereas the PFS benefit was not significant in the PIK3CA mutation strata. Additional analyses are ongoing and will be presented. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr S3-3.

Growth inhibition of PTEN low expressed breast cancer cells induced by combinational therapy with Lapatinib and Src inhibitor-AZD0530

PTEN Activation Sensitizes Breast Cancer to PI3-kinase Inhibitor Through the Β-Catenin Signaling Pathway

Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells

PTEN-mediated Resistance to Tyrosine Kinase Inhibitors in Lung Cancer Cell Lines H-157 and H-1355

Association of Phosphatase and Tensin Homolog Low and Phosphatidylinositol 3-Kinase Catalytic Subunit Alpha Gene Mutations on Outcome in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients Treated with First-Line Lapatinib Plus Paclitaxel or Paclitaxel Alone.

Effects of SRC Inhibition on Survival, Migration and Invasion of Human Breast Cancer Cells Resistant to Lapatinib

S3-3: Association of PTEN Loss and PIK3CA Mutations on Outcome in HER2+ Metastatic Breast Cancer Patients Treated with First-Line Lapatinib Plus Paclitaxel or Paclitaxel Alone.

Inhibition of Phosphoinositide 3-Kinase Enhances the Cytotoxicity of AG1478, an Epidermal Growth Factor Receptor Inhibitor, in Breast Cancer Cells

Association of Epithelial-Mesenchymal Transition with Lapatinib Resistance Through Multipe Pathways Activation in Her2-Positive Breast Cancer.

An Evaluation of Pi3k Pathway Activation on the Efficacy of Both Trastuzumab and Lapatinib

Abstract 2778: Lapatinib Inhibits CIP2A/PP2A/p-Akt Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells

PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway

Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer

PI3K Pathway Activation Results in Low Efficacy of Both Trastuzumab and Lapatinib.

Combining lapatinib and palbociclib inhibits cell proliferation and invasion via AKT signaling pathway in endocrine-resistant breast cancer cells

Synergistic Effects of Anlotinib and DDP on Breast Cancer: Targeting the VEGF/JAK2/STAT3 Axis

Combined Effects Of Lapatinib And Bortezomib In Human Epidermal Receptor 2 (Her2)-Overexpressing Breast Cancer Cells And Activity Of Bortezomib Against Lapatinib-Resistant Breast Cancer Cells

Lapatinib Inhibits Cip2a/Pp2a/P-Akt Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells

Pten Restoration and Pik3cb Knockdown Synergistically Suppress Glioblastoma Growth in Vitro and in Xenografts

Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress

Molecular Mechanism of Synergistic Antitumor Activity and Induced Apoptosis of Zoledronic Acid and Paclitaxel